Drug development: Mix and match.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report.Frontiers in oncology · 2022
   Article
2. LdrB Toxin with In Vitro and In Vivo Antitumor Activity as a Potential Tool for Cancer Gene Therapy.Cancers · 2019
   Article
3. Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review.OncoTargets and therapy · 2018
   Article
4. Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: a meta-analysis based on 24 articles.Oncotarget · 2017
   Article
5. DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle.Molecular and cellular biology · 2016
   Article
6. Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments.Gut microbes · 2016
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as